-DOCSTART- -X- O
Gynecological -X- _ B-Patient
cancers -X- _ I-Patient
are -X- _ O
a -X- _ O
leading -X- _ O
cause -X- _ O
of -X- _ O
mortality -X- _ O
in -X- _ O
women. -X- _ O
CD8 -X- _ O
( -X- _ O
+ -X- _ O
) -X- _ O
T -X- _ O
cell -X- _ O
immunity -X- _ O
largely -X- _ O
correlates -X- _ O
with -X- _ O
enhanced -X- _ O
survival -X- _ O
, -X- _ O
whereas -X- _ O
inflammation -X- _ O
is -X- _ O
associated -X- _ O
with -X- _ O
poor -X- _ O
prognosis. -X- _ O
Previous -X- _ O
studies -X- _ O
have -X- _ O
shown -X- _ O
polystyrene -X- _ O
nanoparticles -X- _ O
( -X- _ O
PSNPs -X- _ O
) -X- _ O
are -X- _ O
biocompatible -X- _ O
, -X- _ O
do -X- _ O
not -X- _ O
induce -X- _ O
inflammation -X- _ O
and -X- _ O
when -X- _ O
used -X- _ O
as -X- _ O
vaccine -X- _ O
carriers -X- _ O
for -X- _ O
model -X- _ O
peptides -X- _ O
induce -X- _ O
CD8 -X- _ O
( -X- _ O
+ -X- _ O
) -X- _ O
T -X- _ O
cell -X- _ O
responses. -X- _ O
Herein -X- _ O
we -X- _ O
test -X- _ O
the -X- _ O
immunogenicity -X- _ O
of -X- _ O
24 -X- _ B-Intervention
different -X- _ I-Intervention
peptides -X- _ I-Intervention
, -X- _ O
from -X- _ O
three -X- _ O
leading -X- _ O
vaccine -X- _ O
target -X- _ O
proteins -X- _ O
in -X- _ O
gynecological -X- _ B-Patient
cancers -X- _ I-Patient
: -X- _ O
the -X- _ O
E7 -X- _ B-Comparison
protein -X- _ I-Comparison
of -X- _ I-Comparison
human -X- _ I-Comparison
papilloma -X- _ I-Comparison
virus -X- _ I-Comparison
( -X- _ I-Comparison
HPV -X- _ I-Comparison
) -X- _ I-Comparison
; -X- _ I-Comparison
Wilms -X- _ I-Comparison
Tumor -X- _ I-Comparison
antigen -X- _ I-Comparison
1 -X- _ I-Comparison
( -X- _ I-Comparison
WT1 -X- _ I-Comparison
) -X- _ I-Comparison
and -X- _ I-Comparison
survivin -X- _ I-Comparison
( -X- _ I-Comparison
SV -X- _ I-Comparison
) -X- _ I-Comparison
, -X- _ I-Comparison
in -X- _ I-Comparison
PSNP -X- _ I-Comparison
conjugate -X- _ I-Comparison
vaccines. -X- _ I-Comparison
Of -X- _ O
relevance -X- _ O
to -X- _ O
vaccine -X- _ O
development -X- _ O
was -X- _ O
the -X- _ O
finding -X- _ O
that -X- _ O
a -X- _ O
minimal -X- _ O
CD8 -X- _ O
( -X- _ O
+ -X- _ O
) -X- _ O
T -X- _ O
cell -X- _ O
peptide -X- _ O
epitope -X- _ O
from -X- _ O
HPV -X- _ O
was -X- _ O
not -X- _ O
able -X- _ O
to -X- _ O
induce -X- _ O
HLA-A2.1 -X- _ O
specific -X- _ O
CD8 -X- _ O
( -X- _ O
+ -X- _ O
) -X- _ O
T -X- _ O
cell -X- _ O
responses -X- _ O
in -X- _ O
transgenic -X- _ O
humanized -X- _ O
mice -X- _ O
using -X- _ O
conventional -X- _ O
adjuvants -X- _ O
such -X- _ O
as -X- _ O
CpG -X- _ O
, -X- _ O
but -X- _ O
was -X- _ O
nevertheless -X- _ O
able -X- _ O
to -X- _ O
generate -X- _ O
strong -X- _ O
immunity -X- _ O
when -X- _ O
delivered -X- _ O
as -X- _ O
part -X- _ O
of -X- _ O
a -X- _ O
specific -X- _ O
longer -X- _ O
peptide -X- _ O
conjugated -X- _ O
to -X- _ O
PSNPs -X- _ O
vaccines. -X- _ O
Conversely -X- _ O
, -X- _ O
in -X- _ O
most -X- _ O
cases -X- _ O
, -X- _ O
when -X- _ O
the -X- _ O
minimal -X- _ B-Outcome
CD8 -X- _ I-Outcome
( -X- _ I-Outcome
+ -X- _ I-Outcome
) -X- _ I-Outcome
T -X- _ I-Outcome
cell -X- _ I-Outcome
epitopes -X- _ I-Outcome
were -X- _ I-Outcome
able -X- _ I-Outcome
to -X- _ I-Outcome
induce -X- _ I-Outcome
immune -X- _ I-Outcome
responses -X- _ I-Outcome
( -X- _ I-Outcome
with -X- _ I-Outcome
WT1 -X- _ I-Outcome
or -X- _ I-Outcome
SV -X- _ I-Outcome
super -X- _ I-Outcome
agonists -X- _ I-Outcome
) -X- _ I-Outcome
in -X- _ I-Outcome
CpG -X- _ I-Outcome
, -X- _ I-Outcome
they -X- _ I-Outcome
also -X- _ I-Outcome
induced -X- _ I-Outcome
responses -X- _ I-Outcome
when -X- _ I-Outcome
conjugated -X- _ I-Outcome
to -X- _ I-Outcome
PSNPs. -X- _ I-Outcome
In -X- _ I-Outcome
this -X- _ I-Outcome
case -X- _ I-Outcome
, -X- _ I-Outcome
extending -X- _ I-Outcome
the -X- _ I-Outcome
sequence -X- _ I-Outcome
around -X- _ I-Outcome
the -X- _ I-Outcome
CD8 -X- _ I-Outcome
( -X- _ I-Outcome
+ -X- _ I-Outcome
) -X- _ I-Outcome
T -X- _ I-Outcome
cell -X- _ I-Outcome
epitope -X- _ I-Outcome
, -X- _ I-Outcome
using -X- _ I-Outcome
the -X- _ I-Outcome
natural -X- _ I-Outcome
protein -X- _ I-Outcome
context -X- _ I-Outcome
, -X- _ I-Outcome
or -X- _ I-Outcome
engineering -X- _ I-Outcome
linker -X- _ I-Outcome
sequences -X- _ I-Outcome
proposed -X- _ I-Outcome
to -X- _ I-Outcome
enhance -X- _ I-Outcome
antigen -X- _ I-Outcome
processing -X- _ I-Outcome
, -X- _ I-Outcome
had -X- _ I-Outcome
minimal -X- _ I-Outcome
effects -X- _ I-Outcome
in -X- _ I-Outcome
enhancing -X- _ I-Outcome
or -X- _ I-Outcome
changing -X- _ I-Outcome
the -X- _ I-Outcome
cross-reactivity -X- _ I-Outcome
pattern -X- _ I-Outcome
induced -X- _ I-Outcome
by -X- _ I-Outcome
the -X- _ I-Outcome
super -X- _ I-Outcome
agonists. -X- _ I-Outcome
Nanoparticle -X- _ O
approaches -X- _ O
, -X- _ O
such -X- _ O
as -X- _ O
PSNPs -X- _ O
, -X- _ O
therefore -X- _ O
may -X- _ O
offer -X- _ O
an -X- _ O
alternative -X- _ O
vaccination -X- _ O
strategy -X- _ O
when -X- _ O
conventional -X- _ O
adjuvants -X- _ O
are -X- _ O
unable -X- _ O
to -X- _ O
elicit -X- _ O
the -X- _ O
desired -X- _ O
CD8 -X- _ O
( -X- _ O
+ -X- _ O
) -X- _ O
T -X- _ O
cell -X- _ O
specificity. -X- _ O
The -X- _ O
findings -X- _ O
herein -X- _ O
also -X- _ O
offer -X- _ O
sequence -X- _ O
specific -X- _ O
insights -X- _ O
into -X- _ O
peptide -X- _ O
vaccine -X- _ O
design -X- _ O
for -X- _ O
nanoparticle-based -X- _ O
vaccine -X- _ O
carriers -X- _ O
. -X- _ O

